Despite the effectiveness of nucleoside/nucleotide analogues in the treatment of chronic hepatitis B (CHB), their long-term administration is associated with the emergence of resistant hepatitis B virus (HBV) mutants. In this study, mutations resulting in antiviral resistance in HBV DNA samples isolated from 23 CHB patients (nine treatment naïve and 14 treated previously) were studied using a line probe assay (INNO-LiPA HBV DR; Innogenetics) and ultradeep pyrosequencing (UDPS) methods. Whilst the INNO-LiPA HBV DR showed no resistance mutations in HBV DNA samples from treatment-naive patients, mutations mediating lamivudine resistance were detected in three samples by UDPS. Among patients who were treated previously, 19 mutations were detected in eight samples using the INNO-LiPA HBV DR and 29 mutations were detected in 12 samples using UDPS. All mutations detected by the INNO-LiPA HBV DR were also detected by UDPS. There were no mutations that could be detected by INNO-LiPA HBV DR but not by UDPS. A total of ten mutations were detected by UDPS but not by INNO-LiPA HBV DR, and the mean frequency of these mutations was 14.7 %. It was concluded that, although INNO-LiPA HBV DR is a sensitive and practical method commonly used for the detection of resistance mutations in HBV infection, UDPS may significantly increase the detection rate of genotypic resistance in HBV at an early stage.
INTRODUCTION
Hepatitis B virus (HBV) is a DNA virus with a 3.2 kb circular genome structure. Due to the presence of a partly double-stranded HBV genome, transformation into covalently closed circular DNA (cccDNA) occurs at the onset of replication. cccDNA can be found only extrachromosomally in the hepatocyte nucleus and is responsible for persistence of HBV in hepatocytes and for the viral reactivation observed after withdrawal of antiviral therapy (Beck & Nassal, 2007; Seeger et al., 2007) . Nucleoside/ nucleotide analogues used in the treatment of chronic hepatitis B (CHB) act by targeting the reverse transcriptase (RT) enzyme, which plays a role in HBV replication and is devoid of proofreading activity, rendering itself vulnerable to a high rate of nucleotide changes (Kidd-Ljunggren et al., 2002; Fung et al., 2011) . The estimated mutation rate of HBV is more than 2610 24 base substitutions per site per year. This is about 100 times higher than that of other DNA viruses (Mahtab et al., 2008) .
As a result of HBV persistence, a high rate of replication and error is observed, and a combination of variants with genetically different properties emerges. Any mutant virus within this virus population may become dominant under conditions that give it a replicative advantage (MargeridonThermet et al., 2009) . Mutation in the region of the polymerase (P) gene is associated with preferential selection during treatment with nucleoside/nucleotide analogues, and these viruses predominate over the time Genetic tests that are often used to detect antiviral resistance include direct PCR sequencing, clone-based sequencing and point-mutation methods. Direct PCR sequencing can detect mutations only when they comprise more than 20 % of the viral population. Compared with direct PCR sequencing, clone-based sequencing has a higher sensitivity in detection of mutations with low prevalence. However, this method is time consuming and costly. The INNO-LiPA (line probe assay) (Innogenetics) based on reverse hybridization focuses on point mutations and can detect variants if they comprise at least 5 % of the viral population. The requirement for a new probe design for each mutant limits the use of INNO-LiPA (Lok et al., 2007) . In contrast, a novel method referred to as ultradeep pyrosequencing (UDPS) has a high processing volume and can detect minor variants within a short period of time (Margeridon-Thermet et al., 2009) .
In this study, antiviral resistance mutations in HBV DNA samples from CHB patients were examined using a reverse hybridization method as well as UDPS.
RESULTS

Patients and samples
A total of 14 patients (ten male, four female) with a mean age of 38.86 years who were treated previously with nucleoside/nucleotide analogues and a total of nine treatment-naive patients (six male, three female) with a mean age of 28.60 years were included in the study. RT gene mutations were tested in serum samples using two different methods, the INNO-LiPA HBV DR version 2 and UDPS. The mean HBV DNA count was 4.9610 7 ) in treatment-naive patients. Whole-genome analysis with UDPS showed the presence of genotype D1 with a frequency of 99.3 % (www.hepseq.org/Public/Tool/genotype_tool.php) in the overall study group. During the process of wholegenome analysis, a total of 59 994 228 sequence readings with a mean of 457 bp were performed. The raw sequences obtained were sorted by barcodes and each individual's sequence reads were determined. Single-nucleotide polymorphisms and deletion-insertion polymorphisms were determined for each patient using the following criteria: (i) variants must be detected in at least three unique (nonduplicate) sequencing readings with both forward and reverse readings; (ii) polymorphisms must have at least a 10 % frequency among the total unique sequencing readings at that location (except for the 727C insertion); (iii) polymorphisms must have high-quality scores (.Q20 for variants and .Q15 for three nucleotides on each side of the variant) (D'Aurelio et al., 2010). The sequence reads were then aligned to the HBV reference sequence (GenBank accession no. AY721608; Bozdayi et al., 2005) .
RT gene mutations (antiviral resistance mutations)
The INNO-LiPA HBV DR could not detect any mutations associated with antiviral resistance in any of the treatmentnaive patients. In the same patient group, with UDPS analysis, as compensatory mutations, which cause lamivudine resistance, V173L (frequency 2.9 %) and L180M (frequency 2.2 %) were detected in one patient, L80V/I in one patient (frequency 1 %) and L180M in another one patient (frequency 7.9 %). The given frequencies are the mutation frequencies within the virus populations in each patient.
The presence of RT gene mutations was shown in eight patients when the INNO-LiPA HBV DR was used and in 12 patients when UDPS was used for the analysis of HBV DNA extracts among the 14 patients who had previously received treatment with nucleoside/nucleotide analogues. The total number of mutations detected by the INNO-LiPA HBV DR was 19, compared with 29 with UDPS. The mean frequency was 52.1 % for these 29 mutations detected by UDPS in HBV DNA extracts of patients who had been treated previously. The mean frequency of 19 mutations detected by the INNO-LiPA HBV DR and UDPS was 71.8 %. The mean frequency of mutations that were missed by the INNO-LiPA HBV DR but detected by UDPS was 14.7 %.
All 12 mutations (seven M204V, three L180M, one L80V and one A181T) detected by UDPS with a frequency of 100 % were also detected using the INNO-LiPA HBV DR. The mutations M204V, A181T, L180M, L80V, L80I, L180M and A181T, which were detected by UDPS with frequencies of 44.4, 33.3, 28.5, 20.0, 16.3, 12 .1 and 10 %, respectively, were also detected by the INNO-LiPA HBV DR. However, the L80V, V173L, T184S, V173L, L180M, V173L, L180M, L180M and A181V mutations, which were detected by UDPS with frequencies of 33, 33, 22.2, 22.0, 7.89, 2.6, 2.5, 2.3 and 1.1 %, respectively, were not detected by the INNO-LiPA HBV DR (Table 1) .
In patients treated previously with nucleoside analogues, the mutation rates for L80V/I, V173L, L180M, A181V/T, T184I, S202G, M204V/I and N236T were calculated for both methods separately. The detection rates for these mutations with the INNO-LiPA HBV DR were 21.4 % (3/14), 0 % (0/ 14), 35.7 % (5/14), 14.3 % (2/14), 0 % (0/14), 7.1 % (1/14), 57.1 % (8/14) and 0 % (0/14), respectively. The corresponding values following UDPS analysis were 28.6 % (4/14), 21.4 % (3/14), 64.3 % (9/14), 21.4 % (3/14), 7.1 % (1/14), 7.1 % (1/ 14), 57.1 % (8/14) and 0 % (0/14), respectively (Fig. 1) .
The following nucleoside/nucleotide analogues were used previously by 14 patients; lamivudine in nine pateints, adefovir in three, entecavir in one and tenofovir in one. Antiviral resistance rates detected by UDPS and the INNOLiPA HBV DR in lamivudine recipients were eight out of nine and seven out of nine, respectively. The corresponding figures for adefovir were three out of three and two out of three, respectively. No mutations associated with tenofovir resistance were detected by either method in one patient who was treated with tenofovir. However, mutations associated with entecavir resistance were detected by both methods in one patient who was treated with entecavir.
The mean duration of treatment among patients with lamivudine-resistant mutations as detected by the INNOLiPA HBV DR was 4 years. The corresponding figure for mutations detected by UDPS was 3.5 years. Patients with adefovir resistance as detected by the INNO-LiPA HBV DR had on average received 3.75 years of treatment, and the corresponding figure for UDPS was 3.1 years. For one case with entecavir resistance as detected by both methods, the mean duration of treatment was 1 year. The mean duration of treatment in patients with antiviral resistance detected by the INNO-LiPA HBV DR or UDPS with respect to treatment type is shown in Fig. 2 . Mutations detected during treatment with nucleoside/nucleotide analogues as well as certain laboratory findings are shown in Table 2 .
Pre-core/core mutations The A1762T, G1764A, G1862A and G1896A (stop codon) pre-core/core mutations were investigated using UDPS in sequences from all study participants. Pre-core/core mutations were present in 69.6 % (16/23) of the patients. Hepatitis e antigen (HBeAg) was negative in 50.0 % (8/16) of the patients with mutations. In two of the seven patients in whom no mutation was found, HBeAg was negative (Table 3) .
Mutations of the X gene region
The following mutations are investigated in the X gene region of HBV DNA sequences of the patients: G1386M, 
The frequency values of the mutations with UDPS were given; they were detected as (+) and (2) with INNO-LiPA HBV DR. Detection of HBV resistance mutations by LIPA and UDPS C1479D, C1485T, A1499B, A1574B, G1613A, C1631T, C1653T, T1753V, A1762T. Among these, only the T1753V mutation was detected with a frequency of 100 and 99.7 %, respectively, in HBV sequences of patient no. 2 and no. 3. None of the other mutations were detected. Examination of the X gene region showed deletions of nt 1756-1772 in HBV DNA sequences from patient no. 6 and no. 9, with frequency rates of 23.0 and 6.0 % for these patients, respectively. Thus, in the overall patient population, the rate of X gene mutations was 13.0 % (4/23).
High-frequency polymorphisms
Whole-genome analysis of HBV sequences showed a high frequency of change in the following nucleotides: A3006G, T2245C, C3159T, C1984A, C2192A, C2119T, A2838G, T1934A, G2146A, G1845A, A1332G, G1080T, A969G, A930G, A7C, A10C, T1912C, T499C, T1250C, C2167T, T1370T, G1757A, G205C, G961A and C3158G. Of these polymorphisms, ten were detected in the P gene, nine in the core (C) gene, one in the surface antigen (S) gene, three in the P/S gene and one in X gene regions. The frequency of polymorphisms in HBV sequences of the patients is shown in Table 4 .
Amino acid substitutions were also analysed and 18 synonymous and seven non-synonymous substitutions were observed. The non-synonymous amino acid substitutions were C3159T (prolineAserine), A2838G (lysineAglutamic acid), T1934A (serineAthreonine), C3158G (histidineAglutamine/serine), T499C (tyrosineAhistidine), T1250C (leucineAproline) and G961A (valineAisoleucine). There were five, one, one and zero non-synonymous amino acid substitutions in the P, S, C and X gene regions, respectively. Details of the distribution of the non-synonymous substitutions for each viral gene region are shown in Table 5 .
DISCUSSION
Antivirals used for CHB treatment inhibit viral polymerase, hence suppressing HBV replication (Fung et al., 2011) . When a nucleotide change occurring in the P gene region during replication results in an amino acid change decreasing the sensitivity to antiviral medications, a genotypic antiviral resistance is said to take place (Lok et al., 2007) . In the case of genotypic resistance, HBV DNA levels are lower compared with treatment initiation due to the decreased ability of the mutant strains to replicate. However, with the emergence of compensatory mutations, the pressure on replication is removed, resulting in a marked increase in HBV DNA (Locarnini, 2008) . The high HBV DNA levels in our participants can probably be explained on the basis of this phenomenon. Among eight previously treated patients with lamivudine resistance (M204V/I), seven also had compensatory mutations (L80V, L180M and V173L). As the time to development of resistance (Fig. 2) correlated with HBV DNA, those with higher HBV DNA levels may represent those with a late diagnosis of resistance. ALT, alanine aminotransferase; AST, aspartate aminotransferase. *Patient notes: 1, pre-cirrhosis; 2, had not used lamuvidine before; 3, cirrhosis; 4, pre-cirrhosis; 5, no regulations in treatment; 6, 7-month pregnant patient who had used lamuvidine for 2 years and, after facing drug resistance, had used adefovir for 3 years, but before pregnancy adefovir treatment was stopped; 7, cirrhosis, with no regulations in treatment; 12, had used lamuvidine for 2 years; 13, pre-cirrhosis, with no regulations in treatment; 16, no regulations in treatment; 19, post-renal transplantation. DAntiviral resistance mutations. L80V/I, V173L, L180M and M204V/I: mutations have an effect on lamuvidine resistance; S202G and T184I: mutations have an effect on entecavir resistance; A181T/ V: mutations have an effect on adefovir resistance.
Treatment success is significantly dependent upon timely and accurate detection of resistance to antiviral agents. In this regard, the INNO-LiPA HBV DR represents a practical point-mutation method commonly used to detect resistant variants of viral populations with a threshold detection level of 5 %. However, the ability of this method to detect antiviral resistance associated only with known mutations only is considered a significant disadvantage (Solmone et al., 2009) .
In contrast, UDPS, a new-generation sequencing technique introduced in recent years, is capable of quickly detecting even variants comprising only 1 % of the viral population. This technology allows the sequencing of larger DNA fragments (500 Mb) with a lower cost (Osborn & Lok, 2006) . In this study, variants of HBV, a highly dynamic virus, were also studied using UDPS to allow the detection of minor variants responsible for the development of antiviral resistance. The data obtained with the use of this method was compared with that obtained with the INNOLiPA HBV DR, a commonly used method in Turkey for the detection of antiviral resistance.
In the study by Solmone et al. (2009) In the study of Solmone et al. (2009) , among previously treated patients, none of the mutations that could be detected by UDPS and had a frequency below 24 % could also be detected by direct PCR sequencing. Some of these mutations (four mutations with a frequency range between 2 and 8 %) were also missed by the INNO-LiPA HBV DR. Although one mutation (M204V) in a patient was determined using the INNO-LiPA HBV DR, there were no mutations that could be detected by both UDPS and direct PCR sequencing, despite repeated tests. It was hypothesized that this finding could stem from artefacts occurring during the INNO-LiPA HBV DR. We concluded that UDPS represents a more sensitive method in the detection of mutations associated with parent drug resistance compared with direct sequencing and the INNO-LiPA HBV DR (Sheldon et al., 2006 was able to detect the following three mutations of major drug resistance in these patients; M204I (frequency 1.3 %), A181T (frequency 1.0 %) and M204I (frequency 1.3 %). In ten samples from five patients treated previously, a total of 13 mutations with a frequency rate between 1.5 and 13 % were detected with UDPS that could not be detected by direct PCR sequencing (Margeridon-Thermet et al., 2009).
In our study, RT gene mutations associated with antiviral resistance were investigated in nine treatment-naive and 14 previously treated CHB patients using the INNO-LiPA HBV DR and UDPS. However, due to financial constraints related to study funding, mutations could not be studied by direct PCR sequencing. With regard to the methods used in our study, the INNO-LiPA HBV DR showed no mutations of antiviral resistance in treatment-naive patients, whereas, using UDPS, the L180M mutation was found in two treatment-naive patients and the V173L mutation was found in one treatment-naive patient. A lower rate of mutations was found among our treatment-naive patients compared with some other studies (Margeridon-Thermet et al., 2009; Solmone et al., 2009) . However, the detection of these mutations at very low frequencies indicates an absence of methodological problems.
In our study, among patients treated previously with nucleoside/nucleotide analogues, RT gene mutations were detected at a rate of 51.14 % with the INNO-LiPA HBV DR and 85.71 % with UDPS. All mutations detected by the INNO-LiPA HBV DR were also detected by UDPS analysis.
The following findings pertain to the frequency of mutations in previously treated patients: (i) the mean frequency of all mutations detected by UDPS was 52.1 %; (ii) the mean frequency of mutations that were detected bythe INNO-LiPA HBV DR and UDPS was 71.8 %; and (iii) the mean frequency of mutations that were missed by the INNO-LiPA HBV DR but could be detected by UDPS was 14.7 %.
Although the mean frequency of mutations detected by the INNO-LiPA HBV DR was high, the frequency range was found to vary between 12.1 and 100 %. All of the mutations detected by UDPS and having a frequency of 100 % were also detected by the INNO-LiPA HBV DR, and these included seven M204V, three L180M, one L80V and one A181T.
The genetic changes that are coded in relation to antiviral resistance decrease the replication capacity of HBV. However, other mutations, which occur additionally, help the virus to recover its replication ability. These compensatory mutations do not occur only in the P gene region. They can also occur in other gene regions overlapping the P gene region or in regulatory gene regions such as the basal core promoter (BCP) (Solmone et al., 2009) . In vitro studies have shown that, in lamivudine-resistant mutants, the pre-core and BCP mutations increased the replication capacity but did not affect the drug sensitivity (Chen et al., 2003; Tacke et al., 2004) . In another study, the relationship between response to adefovir and pre-core and BCP mutations was studied in lamivudine-resistant CHB patients. The viral response to adefovir in patients with pre-core mutations was higher than those without. It was shown that the rates of cumulative viral breakthrough increased in patients with BCP mutations. Pre-core and BCP mutations were also effective in the production of HBeAg. Most of the mutations occurring in these regions form stop codons to prevent HBeAg production (Papatheodoridis & Hadziyannis, 2001) . In a study performed in Korea, whilst T1762/A1764 BCP mutations were found to occur at a rate of 81.4 % in HBeAg-positive patients, the corresponding figure reported was 92.5 % in HBeAg-negative patients. In that study, an A1896 stop codon mutation in the pre-core region was seen more frequently with a rate of 95 % among HBeAg-negative patients. Furthermore, C1802, A1828, T1846, A1850, C1858 and T1862 mutations were also associated with HBeAg negativity in the pre-core region (Choi et al., 2009 ).
In our study, in one of our patients who had received entecavir previously, G1896A mutations were also detected with a frequency of 100 % in addition to mutations associated with lamivudine and entecavir resistance. Following UDPS analysis for HBV sequences among four patients with previous adefovir treatment, three had A181T associated with adefovir resistance along with pre-core/ core mutations and one had mutations of lamivudine resistance along with G1862A (frequency 100 %) and G1896A (frequency 15 %) pre-core/core mutations without mutations of adefovir resistance. It is interesting to observe that pre-core/core mutations along with resistance mutations were also detected in our study.
To the best of our knowledge, in the literature only a single study exists that has examined pre-core mutations by UDPS (Homs et al., 2011) . In that study, the investigators started with the idea that HBV polymerase initiates RT via the encapsidation signal in the pre-genomic RNA, which is located in the pre-core. Thus, they aimed to investigate pre-core mutations along with the mutations of the polymerase in the YMDD region with catalytic activity at the same frequency. However, as there is a distance of 1 kb between these two regions of the HBV genome, it is difficult to perform a concurrent analysis with the classical sequencing method. The investigators created a circular molecule by combining the pre-core and YMDD regions with 59 ends via HindIII-containing primers. They then performed a an ultradeep sequencing analysis. Only in one of the seven patients examined were both YMDD (codon 204) and pre-core (codons 1, 2 and 28) mutations detected with frequencies above 1 % (Homs et al., 2011) .
The HBV X gene encodes the small basic cytoplasmic proteins and is able to transactivate cellular and viral genes, even though it does not show any DNA-related activity (Koike & Takada, 1995) . Furthermore, the proteins synthesized by the X gene region also affect the function of p53, which is a tumour suppressor gene product. Therefore, mutations that occur in X gene region are associated with hepatocellular carcinoma (Cho et al., 2001) . Livezey et al. (2000) demonstrated this relationship in HBV-infected HepG2 cells. We investigated X gene mutations of all CHB patients in the study group in terms of hepatocellular carcinoma risk. T1753V, which is among the explored mutations of the X gene region, together with G1386M, C1479D, C1485T, A1499B, A1574B, G1613A, C1631T, C1653T, T1753V and A1762T, was detected in two patients. In addition, examination of the X gene region showed deletion of nt 1756-1772 in HBV DNA sequences of patients no. 6 and no. 9. Long-term follow-up of these patients will be required to determine the clinical relevance of these mutations. Also, our literature search did not revealed any studies where mutations of the X gene region were investigated by UDPS.
During the final stage of our study, frequent nucleotide changes were examined in all patients. A list of 25 nucleotide changes that were detected in our study is shown in Table 5 .
As can be seen in the table, the majority of these mutations occurred in the P gene region. It is interesting to observe that the C3159T, A2838G, T1934A, C3158G, T499C, T1250C and G961A mutations resulted in non-synonymous amino acid substitutions. A Global Cross-Database NCBI Search that we conducted did not provided any information on the A3006G, C1984A, C2192A, C2119T, A2838G, G1080T, A969G, A930G, T1912C, T1250C, C2167T, T1370T and C3158G polymorphisms. Clinical results for the newly defined mutations can be evaluated only through performing more studies with more samples.
HBV is a dynamic virus and, as a consequence of this feature, high numbers of variants develop in CHB infections. Whilst some of these variants are latent, others may go through significant changes in the course of the disease. In particular, after long-term treatment with nucleoside/nucleotide analogues, these variants may become dominant and result in the development of antiviral resistance. In our patients treated previously with nucleoside/nucleotide analogues, mutations associated with genotypic resistance were analysed using two different methods. The INNO-LiPA HBV DR represents a sensitive and practical method commonly used to detect mutations determining genotypic resistance. However, development of clinical resistance is reflected by a viral break point, where a logarithmic increase of 1 unit occurs in the lowest serum HBV DNA level during treatment. In this regard, our results suggested that genotypic resistance, which occurs significantly earlier (usually months earlier) than the viral break point, can be detected quickly using UDPS, which is sensitive to even minor variants (1 %). This advantage may be especially important in terms of the initiation of 'rescue treatment' as soon as possible.
METHODS
Study group. A total of 23 serum samples from nine treatment-naive patients and 14 patients with previous treatment were included in the study. Whole-genome analysis with UDPS in the overall patient population (treatment naïve and previously treated) showed the presence of genotype D1 in 99 % of the cases. The previously treated patients comprised those who had virological breakthrough during treatment, which is defined as the conversion of HBV DNA negativity to positivity, or a 1 log increase in HBV DNA titre compared with the previous value.
This study was conducted at the Virology and Basic Immunology Unit, Department of Microbiology and Clinical Microbiology, Istanbul University Faculty of Medicine, in the context of routine examination of antiviral resistance with a reverse hybridization method. Patients included in the study had serum HBV DNA levels above 10 000 IU as detected by a real-time PCR method (COBAS AmpliPrep/COBAS TaqMan; Roche).
Whole-genome analysis was carried out using a UDPS method on HBV DNA extracts of the patients, and antiviral resistance mutations were studied routinely with reverse hybridization. UDPS analyses were performed at the Institute of Experimental Medicine, Whole Genome Laboratory, Istanbul University.
HBV DNA extraction. A QIAamp DNA Mini kit (Qiagen) was used for extraction of HBV DNA from the patient's serum samples. Extraction was performed according to recommendations of the manufacturer. Twenty microlitres of the obtained HBV DNA extracts was used to investigate antiviral resistance mutations by reverse hybridization. The remaining amount was stored at 220 uC for UDPS analysis.
Investigation of antiviral resistance mutations with reverse hybridization. Viral P gene mutations associated with the development of resistance to nucleoside/nucleotide analogues were studied with a reverse hybridization method (INNO-LiPA HBV DR version 2; Innogenetics). Before proceeding to the hybridization stage, HBV DNA extracts were amplified using the primer mixture, which is biotinylated towards the A-F domains of the viral polymerase, in the INNO-LiPA HBV DR kit. After the amplification products were checked by 2 % agarose gel electrophoresis, mutations that cause antiviral resistance were studied by reverse hybridization using the INNO-LiPA HBV DR.
Investigation of antiviral resistance mutations by UDPS.
Conserved HBV genomic sequences from the NCBI database (http://www.ncbi.nlm.nih.gov/) were chosen to design six pairs of barcoded amplicon primers (Table 6 ) to amplify the whole genome using PCR. Barcoded amplicon primers were designed according to GS FLX 454 recommendations (http://www.454.com). All fragments were amplified using a proofreading enzyme (Fast Start High-Fidelity Taq DNA polymerase; Roche). HBV DNA (100 ng) was added to the PCR mix with 50 mM dNTPs, 1.5 mM MgCl 2 , 10 pmol primers and 0.15 U Fast Start High-Fidelity Taq DNA polymerase. PCR was carried out as follows: one cycle at 95 uC for 3 min, and 35 cycles at 94 uC for 30 s, 56 uC for 30 s and 72 uC for 30 s, with a final cycle at 72 uC for 5 min.
UDPS and bioinformatics. Overlapping PCR products (~457 bp) were purified with a QIAspin Mini-Elute Spin kit (Qiagen). Nextgeneration sequencing was performed using the GS FLX 454 system (Roche). PCR-amplified DNA was used to generate an amplicon library according to the manufacturer's protocol (Roche Diagnostics). DNA fragments were purified with the Mini-Elute kit and fragment size and quality was verified using an Agilent Bioanalyser 2100 (Agilent Technologies). GS FLX runs were performed in a 16-lane gasget picotitre sequencing plate, and GS FLX kits were used to produce UDPS according to the manufacturer's protocol (Roche Diagnostics). AVA (Roche) and Sequencher (Genes Codes Corp.) software were used to analyse the UDPS results.
Sequence reads were aligned to the reference sequence (GenBank accession no. AY721608) using the sequence alignment method of Smith & Waterman (1981) with the strict criteria of minimum 95 % match ratio and 50-base coverage. For detection and correction of read errors, an error fix procedure was then performed (Eriksson et al., 2008) . For each position in the reference, corresponding bases from aligned fragments were gathered to examine whether a minor set of mutations indicating the existence of a possible haplogroup were present at that position or not. To access the significance of a minor variation, a binomial test was run with the sequencing error rate e50.0025 to find the P value of each variation group. Variations with P values lower than 0.001 were accepted as misreads to be fixed. Others with P values over 0.001 were considered as the mutations that could form a haplogroup. In order to form a consensus on misreads, the reference line was divided into windows of 20 bases wide. Among these windows, only those possessing 100 or more fragments were used for error correction (23 windows). In the following step, a haplogroup detection procedure was performed to find the number of haplogroups, k, in this window. Not only single mutations but also pairs of mutations can form a haplogroup. To evaluate the significance of a haplogroup formed by a mutation pair, Fisher's exact test was used with a significance level of 0.001. After that, for each window, a k-means clustering algorithm was performed to group fragments of each window into k groups. In this way, misreads could be fixed according to the consensus of each group. During the correction procedure, it was observed that the richest region for G+C counts (from nt 1801 to 1820 with a G+C ratio of 63.6 mol% and 43 haplogroups) had an error rate of 0.0035 whilst a G+C-poor region (from nt 2741 to 2760 with a G+C ratio of 26.4 mol% and 44 haplogroups) had an error rate of 0.0072. This study is supported by the University of Istanbul Scientific Research Unit with Project No. 10282.
